Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia
- 7 October 2003
- Vol. 98 (10), 2095-2104
- https://doi.org/10.1002/cncr.11791
Abstract
Gemtuzumab ozogamicin (GO) is a chemotherapeutic agent that consists of a humanized anti‐CD33 antibody (hP67.6) linked to N‐acetyl‐γ calicheamicin 1,2‐dimethyl hydrazine dichloride, a potent enediyne antitumor antibiotic. GO was approved conditionally by the Federal Drug Administration in May 2000 as single‐agent therapy for first recurrence of acute myeloid leukemia (AML) in a subset of older patients. Data on studies in AML with GO‐based regimens have been reported rapidly in addition to new observations on the target antigen, CD33. These data indicate promising new areas of investigation with GO, including its application as maintenance therapy in patients with AML and as an induction and/or maintenance agent in patients with acute promyelocytic leukemia;, and they also have highlighted challenges in the development of GO, particularly its association with hepatic venoocclusive disease. In vitro data on the mechanism of action of GO may be particularly helpful in the design of future clinical studies. Cancer 2003. © 2003 American Cancer Society.Keywords
This publication has 48 references indexed in Scilit:
- Monoclonal antibody therapies in leukemiasSeminars in Hematology, 2002
- Fatal Hepatic Veno-Occlusive Disease in a Phase I Study of Mylotarg and Troxatyl in Patients with Refractory Acute Myeloid Leukemia or Myelodysplastic SyndromeActa Haematologica, 2002
- Gemtuzumab ozogamicin (Mylotarg) monotherapy for relapsed AML after hematopoietic stem cell transplant: efficacy and incidence of hepatic veno-occlusive diseaseBone Marrow Transplantation, 2002
- Acute Myeloid LeukemiaHematology, 2002
- Development of hepatic veno-occlusive disease after Mylotarg infusion for relapsed acute myeloid leukemiaBone Marrow Transplantation, 2001
- Pharmacokinetics of Gemtuzumab Ozogamicin, an Antibody‐Targeted Chemotherapy Agent for the Treatment of Patients with Acute Myeloid Leukemia in First RelapseThe Journal of Clinical Pharmacology, 2001
- Antibody Therapy of Acute Myelogenous LeukemiaCancer Biotherapy & Radiopharmaceuticals, 2000
- Veno-occlusive disease of the liverCurrent Opinion in Oncology, 2000
- Solution structure of the calicheamicin γ1I-DNA complexJournal of Molecular Biology, 1997
- Synthetic calicheamicin mimics with novel initiation mechanisms: DNA cleavage, cytotoxicity, and apoptosisCell Chemical Biology, 1994